

## Cellnovo's Diabetes Management System selected for inclusion in EUR 4 million diabetes self-management project

*Three-year project funded by European Commission's Horizon 2020 programme*

**Paris, France, April 13, 2016** – Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, announces that it has been selected to participate in a project, funded by the European Commission's Horizon 2020 programme, aimed at investigating new technologies to help improve the lives of people with Type 1 diabetes.

The project, named PEPPER (Patient Empowerment through Predictive Personalised decision support), has a budget of nearly EUR 4 million and brings together leading UK and European universities and companies to research and develop technology that will help to improve the self-management of people with Type 1 diabetes.

Researchers working on the project will use Cellnovo's diabetes management system to create a personalised decision support system that will make predictions based on real-time data in order to empower individuals to self-manage their condition. The design of the system will involve patients, clinicians and carers at every stage to ensure that it meets user needs.

**Sophie Baratte, Chief Executive Officer of Cellnovo, commented:** *“We are delighted to be participating in PEPPER, which we believe is a strong endorsement of our proprietary technology. The Cellnovo diabetes management system is an ideal platform for a personalised decision support system because of its real-time connected data, as well as its wearability and discreetness. The funding by the European Commission's Horizon 2020 programme further demonstrates its key role in this pioneering area of diabetes research.”*

The system will have a strong emphasis on safety and will include features such as glucose level predictions, dose advice, and alarms to raise the individuals' awareness of the risk of hypoglycaemia and hyperglycaemia. By preventing adverse episodes such as these, the system will improve lifestyle, monitoring and quality of life for patients, as well as strengthening their interactions with healthcare professionals. The tool will offer bespoke advice by integrating personal health systems with broad and various sources of physiological, lifestyle, environmental and social data, together with an unobtrusive patch pump.

Research will be conducted into the development of artificial intelligence combined with predictive computer modelling, both of which will be integrated into the system. The project will also examine the extent to which human behavioural factors and usability issues have previously hindered the wider adoption of personal guidance systems for chronic disease self-management.

The project, led by Oxford Brookes University, will run until January 2019 and includes the following partner institutions from three EU member states: Imperial College London, University de Girona, Girona Biomedical Research Institute – Hospital Dr. Josep Trueta Romsoft SRL and Cellnovo.

**Clare Martin, Oxford Brookes University, commented:** *“We believe that better use of data and technology has the power to improve health, transforming the quality and reducing the cost of health and care services. Cellnovo's innovative technology, empowering diabetes patients to accurately self-*

*manage their condition, fits perfectly with the overall aim of the PEPPER project. We are delighted to be working with them.”*

*This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 689810.*

•••

**In the coming months, Cellnovo will participate in the following investor event:**

- Healthcare Forum – Société Générale, June 28, Paris

**About Cellnovo (Euronext: CLNV)**

An international commercial medical technology company, Cellnovo markets the first mobile, connected all-in-one diabetes management system, a disruptive technology enhancing daily disease management for Type 1 diabetes patients. Cellnovo’s device currently addresses the \$2.2 billion insulin pump market and the Company is reviewing the potential for the device to serve other markets. Cellnovo is currently marketing the device in the UK, France and The Netherlands and has a clearly defined commercial and manufacturing strategy supported by strategic partners Air Liquide and Flextronics. Cellnovo is headquartered in Paris, France, with product development facilities in Wales, UK. For further information please visit [www.cellnovo.com](http://www.cellnovo.com)

**About the Cellnovo Diabetes Management System**

Compact, tubeless, intuitive and entirely connected, Cellnovo’s insulin patch pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections with drop-by-drop precision, whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real-time.

**Contact**

**Cellnovo**

Chief Executive Officer  
Sophie Baratte  
[investors@cellnovo.com](mailto:investors@cellnovo.com)

**NewCap**

Investor Relations  
Tristan Roquet Montégon  
+ 33 1 44 71 00 16

**Consilium Strategic Communications**

Media Relations in the United Kingdom  
Amber Fennell, Chris Gardner, Chris Welsh, Laura Thornton  
+44 20 3709 5700  
[cellnovo@consilium.com](mailto:cellnovo@consilium.com)

Media Relations in France  
Nicolas Merigeau  
+ 33 1 44 71 94 98  
[cellnovo@newcap.eu](mailto:cellnovo@newcap.eu)

Cellnovo is listed on Euronext,  
Compartment C  
ISIN: FR0012633360 – Ticker:  
CLNV

